Thursday, July 9, 2026

biotech · Cervical Spinal Cord Injury · Spinal Cord Injury · LCTX

Lineage Cell Therapeutics

Lineage Cell Therapeutics clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Carlsbad, USA HQ
1990 Founded
35 Employees
Public company Type
LCTX · NYSE Ticker
Company details
Status
Public
HQ
Carlsbad, USA
Founded
1990
Employees
35
Programs
3
Drugs
0
Patents
0
Intelligence · Clinical Programs

Lineage Cell Therapeutics projects

3 ClinicalTrials.gov programs sponsored by Lineage Cell Therapeutics.

Lineage Cell Therapeutics has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. AST-OPC1

    Lineage Cell Therapeutics

    Cervical Spinal Cord Injury

    phase 2 mab completed

    1 trial
  2. GRNOPC1

    Lineage Cell Therapeutics

    Spinal Cord Injury

    phase 1 mab completed

    1 trial
  3. OPC1

    Lineage Cell Therapeutics

    Spinal Cord Injury Cervical

    phase 1 mab active

    1 trial

Frequently asked questions

How many clinical projects does Lineage Cell Therapeutics have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.